Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Investors also drew comfort from positive management commentary on increased client inquiries and on-site customer visits, ...

The Ministry for Primary Industries expects it could take months to repopulate an Otago poultry farm that tested positive for ...

RBC Capital analyst Sean Dodge maintained a Hold rating on Avid Bioservices (CDMO – Research Report) on January 8 and set a price target of ...

Eversana has acquired pharmaphorum parent Healthware Group in a move that elevates the longstanding partnership between the companies, expands their geographic reach, and furthers their ambition ...

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new menopause therapy Veozah ...